Ascentage Pharma Group International - Unsponsored ADR
AAPG Healthcare Biotechnology
Ascentage Pharma Group International - Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $82.1 million, down 38.9% from fiscal 2024.
Follow AAPG
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Cash and Short Term Investments |
353.22 | 172.79 | 150.52 |
Receivables |
36.17 | 11.39 | 20.08 |
Inventory |
4.09 | 0.90 | 2.23 |
Total current assets |
421.01 | 201.96 | 184.97 |
Property, Plant, Equpment (Net) |
111.72 | 116.37 | 124.64 |
Long-Term Investments |
5.30 | 4.64 | 2.61 |
Goodwill and Intangible Assets (Total) |
12.96 | 13.80 | 15.16 |
Long Term Assets (Tax, Deferred) |
4.57 | 6.06 | 8.24 |
Long-term assets (Other) |
4.39 | 8.13 | 1.41 |
Total non-current assets |
145.77 | 156.68 | 159.10 |
Total Assets |
566.78 | 358.64 | 344.07 |
Accounts Payable |
15.26 | 12.60 | 9.97 |
Current Part of Debt |
174.81 | 106.73 | 84.82 |
Other current liabilities |
5.36 | 5.14 | 5.29 |
Total current liabilities |
235.00 | 159.83 | 128.55 |
Long Term Debt (Total) |
108.28 | 121.85 | 162.26 |
Non-current Revenue (Deferred) |
0.93 | 3.77 | 5.00 |
Long Term Tax Liability (Deferred) |
— | 0.74 | 1.45 |
Non-current Liabilities (Other) |
31.78 | 34.90 | 37.08 |
Total non-current liabilities |
141.00 | 161.25 | 205.80 |
Total liabilities |
375.99 | 321.08 | 334.35 |
Additional Paid In Capital |
1,218.28 | 844.00 | 767.79 |
Common Stock (Net) |
0.04 | 0.03 | 0.03 |
Retained Earnings |
(1,002.89) | (790.56) | (738.26) |
Treasury Stock |
0.42 | 0.00 | 2.94 |
Shareholders Equity (Other) |
(25.61) | (17.27) | (18.30) |
Common Equity (Total) |
190.79 | 37.56 | 9.72 |
Shareholders Equity (Total) |
190.79 | 37.56 | 9.72 |
Shareholders Equity and Liabilities (Total) |
566.78 | 358.64 | 344.07 |
Shares (Common) |
93.33 | 78.81 | 72.55 |
Shareholders Equity (Tangible) |
177.83 | 23.77 | (5.44) |
Net Debt |
(70.12) | 55.80 | 96.57 |
Total Debt |
283.10 | 228.58 | 247.08 |